Association of gestational maternal hypothyroxinemia and increased autism risk by Román, C. (Concepción) et al.
ORIGINAL ARTICLE
Association of Gestational
Maternal Hypothyroxinemia
and Increased Autism Risk
Gustavo C. Roman, MD,1,2 Akhgar Ghassabian, MD, PhD,3,4
Jacoba J. Bongers-Schokking, MD, PhD,5,6 Vincent W. V. Jaddoe, MD, PhD,3,5,7
Albert Hofman, MD, PhD,3,5 Yolanda B. de Rijke, PhD,8,9
Frank C. Verhulst, MD, PhD,4 and Henning Tiemeier, MD, PhD4,5,10
Objective: Transient gestational hypothyroxinemia in rodents induces cortical neuronal migration brain lesions resem-
bling those of autism. We investigated the association between maternal hypothyroxinemia (gestational weeks 6–18)
and autistic symptoms in children.
Methods: The mother-and-child cohort of the Generation R Study (Rotterdam, the Netherlands) began prenatal
enrollment between 2002 and 2006. At a mean gestational age of 13.4 weeks (standard deviation 5 1.9, range 5
5.9–17.9), maternal thyroid function tests (serum thyrotropin [TSH], free thyroxine [fT4], and thyroid peroxidase [TPO]
antibodies) were assessed in 5,100 women. We defined severe maternal hypothyroxinemia as fT4 < 5th percentile
with normal TSH. Six years later, parents reported behavioral and emotional symptoms in 4,039 children (79%) using
the Pervasive Developmental Problems (PDP) subscale of the Child Behavior Checklist and=or the Social Responsive-
ness Scale (SRS). We defined a probable autistic child by a PDP score > 98th percentile and SRS score in the top 5%
of the sample (n 5 81, 2.0%).
Results: Severe maternal hypothyroxinemia (n 5 136) was associated with an almost 4-fold increase in the odds of
having a probable autistic child (adjusted odds ratio 5 3.89, 95% confidence interval [CI] 5 1.83–8.20, p < 0.001).
Using PDP scores, children of mothers with severe hypothyroxinemia had higher scores of autistic symptoms by age
6 years (adjusted B 5 0.23, 95% CI 5 0.03–0.37); SRS results were similar. No risk was found for children of TPO-
antibody–positive mothers (n 5 308).
Interpretation: We found a consistent association between severe, early gestation maternal hypothyroxinemia and
autistic symptoms in offspring. Findings are concordant with epidemiological, biological, and experimental data on
autism. Although these findings cannot establish causality, they open the possibility of preventive interventions.
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The cause of autism spectrum disorders (ASD) remainsunknown despite advances in genetic research,1 sug-
gesting a possible etiologic role of environmental fac-
tors; autism risk increases with older parental age,2
prenatal medications, gestational bleeding, and
diabetes.3
In 1999, Haddow et al4 demonstrated that mater-
nal hypothyroidism during pregnancy affects cognitive
development of the child; Morreale de Escobar and her
colleagues further delimited critical thyroid brain effects
to first-trimester maternal hypothyroxinemia, defined as
low-for-gestational-age circulating maternal free thyroxine
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(fT4) with normal or increased thyrotropin (TSH).
5,6 A
series of elegant animal models from her research group
demonstrated that transient and mild fT4 deficits during
early gestation produce permanent abnormalities in corti-
cal development of the progeny, causing faulty neuronal
migration in hippocampus and somatosensory cortex.7–9
Cortical layers were blurred, irregular, and lacking corti-
cal barrels, with neurons in abnormal locations, including
white matter.7,8 Thyroid deficits, as short as 3 days in
rodents, induced permanent alterations of cortical brain
cytoarchitecture, radial distribution of neurons, and
abnormal tangential migration of medial ganglionic-
eminence–derived neurons.9 In humans, neocortical
development occurs between weeks 6 and 24 of gesta-
tion, although the bulk of cortical cell migration occurs
between 8 and 24 weeks, before the onset of fetal thyroid
hormone secretion at midgestation (weeks 18–22).
In 2007, Roman10 discerned the remarkable histo-
logical similarities existing between the neuropathology
of autism11 and the brain lesions of experimental mater-
nal hypothyroxinemia7–9; he postulated that maternal fT4
deficiency in early gestation could be important in
autism by disrupting critical stages of neuronal migration
in brain and cerebellum. Recently, Hoshiko et al12 found
that infants born with very low fT4 had an increased risk
of autism.
To investigate the role of maternal hypothyroxine-
mia, we analyzed maternal thyroid function during preg-
nancy and autistic symptoms data from the Generation
R Study (Rotterdam, the Netherlands), a unique cohort
that has already contributed important information on
thyroid function and cognitive, behavioral, and psycho-
motor development.13–15 We explored the relation
between thyroid function tests at 6 to 24 weeks of gesta-
tion and parent-reported autistic symptoms in children at
6 years of age, controlling for maternal factors and child-
ren’s characteristics.
Subjects and Methods
Participants
The Generation R Study is a population-based birth cohort
designed to identify early environmental and genetic determi-
nants of growth, development, and health from fetal life
onward.16,17 Erasmus Medical Center, Rotterdam, the Nether-
lands, and Methodist Research Institute, Houston, Texas
approved this study. Written informed consent was obtained
from adult participants, and all data were deidentified. Parents
were not informed about test results (except 1 case, excluded
from this study).
In total (Fig 1), 8,879 pregnant women were enrolled
during pregnancy (7,069 women in early pregnancy, 1,594 in
midpregnancy, and 216 in late pregnancy), and 7,510 con-
sented for pre- and postnatal participation; fT4 levels were
measured in 5,100 women in early pregnancy (<18 weeks of
gestation). Information on autistic symptoms was available in
4,039 children (79%) at 6 years of age. All children were born
between April 2002 and January 2006.
Children’s Autistic Symptoms
We assessed parent-reported autistic symptoms using 2 instru-
ments: the Pervasive Developmental Problems (PDP) subscale
FIGURE 1: Study population.
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of the Child Behavior Checklist for Toddlers (CBCL11=2-5)
18
and the Social Responsiveness Scale (SRS).19 As part of the
Generation R protocol, parents responded to multiple question-
naires from the neonatal period until 6 years of age; therefore,
we consider responses at 6 years of age to be accurate.
PDP SUBSCALE OF THE CBCL11=2-5. The CBCL11=2-5
is a highly validated instrument to measure behavioral and
emotional problems of children at young age.18 The Dutch ver-
sion is reliable and well validated,20 and the subscales for syn-
dromes derived from the CBCL11=2-5 had good fit in 23
international studies across diverse societies,21 and are consistent
with diagnostic categories of the Diagnostic and Statistical
Manual of Mental Disorders, 4th edition (DSM-IV).22 The
PDP subscale of the CBCL11=2-5 is a useful screening instru-
ment to identify children with ASD,23 with good predictive
validity identifying preschoolers at risk of ASD.24 Although
40% of children were 6 years or older at the time of assessment
(mean age 5 72.2 months, standard deviation [SD] 5 4.7,
range 5 57.7–95.9), we used the CBCL11=2-5 (preschool ver-
sion) both for reasons of continuity and because many children
were not yet in formal schooling. In our sample, Cronbach
alphas for the PDP scale in 5-year-old children and in children
older than 5 years were similar (alpha 5 0.79 vs 0.73), indicat-
ing that autistic symptoms were reliably measured in children
older than 5 years.
SRS. To minimize subject burden, the lengthy original ques-
tionnaire was reduced to an 18-item short-form SRS for assess-
ment of autistic behaviors based on parents’ observations of
children’s social behavior in a naturalistic setting19; items selected
encompassed all DSM-IV autism domains (personal communica-
tion with SRS test developer; see Supplementary Table 1). Previ-
ously, another SRS short version (11 items) was validated to
assess autistic behaviors in young Australian twins.25 Each item
is rated from 0 (never true) to 3 (almost always true), covering
social, language, and repetitive behaviors; higher scores indicate
more problems. Mean age at time of SRS assessment was 73.8
(SD 5 5.6) months, with good correlation between SRS and
PDP scores (r 5 0.6, p < 0.001, n 5 3,141).
Maternal Thyroid Parameters
Maternal thyroid parameters (TSH, fT4, and thyroid peroxidase
[TPO] antibodies) were assessed in blood samples obtained
during the first prenatal visit (mean 5 13.4 weeks, SD 5 1.9,
range 5 5.9–17.9). Within 24 hours, plasma was stored at
280C and processed in batches over 6 months using chemilu-
minescent assays (Vitros ECI Immunodiagnostic System; Ortho
Clinical Diagnostics, Rochester, NY). Our laboratory reference
value is fT4 5 11 to 25pmol=l for nonpregnant women. Inter-
and intra-assay coefficients of variation for fT4 were 4.7 to
5.4% and 1.4 to 2.7%. We defined mild maternal hypothyroxi-
nemia (n 5 295, 73% of the sample) in early pregnancy as
normal TSH (>0.03, <2.5mIU=l) and fT4 < 11.82pmol=l
(<10th percentile of the sample) and severe maternal hypothyr-
oxinemia (n 5 136, 3.4% of the sample) as fT4 <
10.99pmol=l (<5th percentile).15 To explore a dose–effect rela-
tion between maternal hypothyroxinemia and autistic symptoms
in the children, we defined a group of “only mild hypo-
thyroxinemia” that consisted of pregnant women with normal
TSH levels and 10.99 < fT4 < 11.82pmol=l (n 5 159). We
measured maternal TPO antibodies (Phadia 250 immunoassay;
Phadia, Uppsala, Sweden) and defined positive TPO antibodies
by plasma concentrations  100IU=ml.
Previous Generation R cohort studies13–15 demonstrated
that maternal TSH is not a good predictor of cognitive and
behavioral problems in the offspring.15 In contrast, low mater-
nal fT4 predicted delays in nonverbal cognitive functions and
expressive language (odds ratio [OR] 5 2.03, 95% confidence
interval [CI] 5 1.22–3.39, p 5 0.007).15 Therefore, low
maternal fT4 concentrations appear to affect fetal brain develop-
ment despite normal TSH levels in pregnant women.15 We
included TPO antibodies because children of TPO antibody–
positive mothers were at a higher risk of attention deficit=hy-
peractivity problems (OR 5 1.77, 95% CI 5 1.15–2.72, p 5
0.01), with minimal influence of maternal TSH on the risk.13
Covariates
Potential confounders were selected a priori.14,15,26 Information
on birth date, sex, and birth weight was obtained from regis-
tries. Gestational age at birth was established using the ultra-
sound examination during pregnancy. Parity, parental age,
education, marital status, ethnicity, and history of smoking
were assessed by questionnaires. Each child’s ethnic background
was defined based on the country of birth of the parents and
classified as Western or Non-Western according to Statistics
Netherlands.27
Maternal education was defined by the highest completed
education. Maternal smoking was assessed at enrollment and in
mid and late pregnancy. We used the Brief Symptom Inventory
(BSI), a 53-item validated self-report questionnaire, to measure
maternal psychopathology during pregnancy.28 High validity and
reliability have been reported for the BSI Dutch translation.29
Maternal folate30 and C-reactive protein (CRP)31 concen-
trations were analyzed in plasma samples in early pregnancy by
using an immunoelectrochemiluminescence assay on the Archi-
tect System (Abbott Diagnostics, Hoofddorp, the Netherlands).
Intelligence was assessed by having the children complete 2 subt-
ests (Mosaics and Categories) of the Snijders-Oomen Niet-ver-
bale intelligentie Test–Revisie.32 In an unrelated sample of 626
children (mean age 5 6.0 years; SD 5 0.85), the correlation
between the sum of these 2 subtests and the full intelligence
quotient (IQ) battery was very high, r 5 0.86 (P. Tellegen, per-
sonal communication). The raw test scores were converted into
nonverbal intelligence score using norms tailored to exact age.32
Statistical Analysis
All children with data on maternal fT4 and 1 or more measures
of autistic symptoms were included in the analyses. In our sam-
ple, missing values of the covariates ranged between 0 and
10%, except for maternal psychopathology scores (13%) and
children’s intelligence. The missing values for the PDP and the
SRS scores were 3.8% and 18.0%, respectively. We used
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independent sample t tests and chi-square statistics to determine
whether the response to the outcome measures of autistic behav-
ior was selective. Missing values were imputed using multiple
imputations. Thirty copies of the original data set were gener-
ated, with missing values replaced by values randomly generated
from the predictive distribution on the basis of the correlation
between the variable with missing values and other variables (for
complete case analyses, see Supplementary Tables 2 and 3).
Early gestation maternal thyroid functions were determi-
nants in all analyses. Maternal TSH and fT4 levels were divided
by SD so that their associations with children’s autistic symp-
toms could be interpreted via SD increments in the predictor.
Children’s SRS and PDP scores were used as outcomes in con-
tinuous analyses to obtain higher power and categorically to
facilitate the clinical interpretation of the findings. In the con-
tinuous analyses, the SRS and PDP scores were transformed
using square root to satisfy the assumption of normality in the
linear regression models.
We used the 93rd (borderline) and 98th (clinical) percen-
tile of a Dutch norm group as cutoff scores to classify children
with behavioral problems within the borderline and clinical
range of the PDP.18 On the PDP scores, 263 children were bor-
derline and 123 were in the clinical range. We explored the
associations between maternal thyroid function and both bor-
derline and clinical PDP using multivariate logistic regressions.
We defined a probable autistic child by stringent criteria
that included a PDP score > 98th percentile and also a SRS
score in the top 5% of the sample (n 5 80, 2.0%). The odds of
being a probable autistic child were calculated using multivariate
logistic regressions, if the mother had maternal hypothyroxinemia
in comparison with the rest of the mother–child cohort.
Furthermore, we performed a sensitivity analysis in a
sample of women with fT4 values measured in the first trimes-
ter of pregnancy (gestation age at the time of blood sampling
< 13 weeks, n 5 1,902).
All models were adjusted for child’s sex, ethnicity, gesta-
tional age at birth, birth weight, parental age, education, smok-
ing history, prenatal psychopathology, thyroid medication
during pregnancy, parity, marital status, time of thyroid sam-
pling, and early pregnancy folate and CRP. All these variables
(except parity) were associated with children’s autistic symptoms
in univariate analyses. Additionally, we adjusted all the analyses
for children’s intelligence because of the possible impact of IQ
differences on the observed association between low maternal
thyroid function and autistic symptoms.
Attrition Analysis
We found differences between the 4,039 mother–child pairs
included in the analyses and the 1,061 (21% of 5,100) pairs
excluded because of missing information on autistic behavior.
Excluded children were mostly non-Western (52.2% vs 26.4%,
p < 0.001), and had a lower birth weight (mean difference 5
2114 g, p < 0.001); their mothers were younger (mean differ-
ence 5 22.9 years, p < 0.001), less educated (10.6% vs
28.9% higher education, p < 0.001), more likely to smoke
(33.9% vs 22.8%, p < 0.001), and had a higher prenatal psy-
chopathology score than those included (mean difference score
5 0.14, p < 0.001). Maternal TSH levels were higher in the
children excluded than those in the analysis (mean difference 5
20.19, p 5 0.04). However, there were no differences in
maternal fT4 between the 2 groups.
Results
In our study, 80 children were defined as a probable
autistic child, having a PDP score (>98th percentile)
within the clinical range, plus SRS scores in the top 5%
of the sample. We found that the odds of being a proba-
ble autistic child increased almost 4-fold (adjusted OR 5
3.89, 95% CI 5 1.83–8.20) when the mother had severe
hypothyroxinemia in early gestation.
Maternal and child characteristics in the study sam-
ple are presented in Table 1. There was no association
between maternal TSH and fT4 during early pregnancy
and children’s borderline and clinical PDP. However, we
found a consistent association between maternal hypo-
thyroxinemia and parent-reported autistic symptoms in
the offspring (Table 2). Severe maternal hypothyroxine-
mia during early gestation was associated with double
risk of borderline PDP at age 6 years (adjusted OR 5
2.02, 95% CI 5 1.16–3.51). Similarly, children of hypo-
thyroxinemic mothers had higher odds of developing
clinical PDP at 6 years (adjusted OR 5 2.60, 95% CI
5 1.30–5.18). The relation between maternal hypothyr-
oxinemia and children’s autistic symptoms, as rated by
the PDP subscale of the CBCL11=2-5, was not dose
dependent, considering the negative association of only
mild hypothyroxinemia in mothers during early preg-
nancy and autistic symptoms.
As shown in Table 3, results of the association anal-
yses with PDP and SRS scores as continuous outcomes
showed similar findings (adjusted B 5 0.23 for PDP,
95% CI 5 0.07–0.37; and adjusted B 5 0.05 for SRS,
95% CI 5 0.01–0.10). There was no relation between
only mild hypothyroxinemia in mothers and children’s
autistic symptoms. Figure 2 illustrates the mean SRS
scores in 3 groups of children based on maternal thyroid
function in early pregnancy. Positive maternal TPO anti-
bodies were not associated with autistic symptoms in the
children (see Tables 2 and 3).
In analyses additionally adjusted for children’s intel-
ligence, the effect estimates decreased but remained sig-
nificant (OR for a probable autistic child 5 3.61, 95%
CI 5 1.70–7.70, p 5 0.001). Similarly, we found that,
when additionally adjusted for children’s intelligence,
children exposed prenatally to maternal severe hypothyr-
oxinemia were more likely to have higher scores on both
the PDP (B 5 0.21, 95% CI 5 0.06–0.36) and SRS
(B 5 0.05, 95% CI 5 0.01–0.09).
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When we restricted the sample to only mother-
child pairs with thyroid parameters assessed in the
first trimester of pregnancy, similar results emerged
(Supplementary Tables 4 and 5). There was no sex
difference in the relation between maternal hypothyr-
oxinemia and autistic symptoms in the offspring (data
not shown).
Discussion
In the present study, we found that severe maternal
hypothyroxinemia in early gestation was associated with
significant increase in the risk of parent-reported autistic
symptoms in the offspring by 6 years of age. Although
these findings cannot establish causality, they suggest that
maternal thyroid dysfunction could result in autistic
TABLE 1. Maternal and Child Characteristics, n 5 4,039
Characteristic Values
Maternal
Age at enrollment, yr, mean (SD) 31.2 (4.7)
Parity, No. primipara [%] 2,419 [59.9]
Marital status, No. single [%] 388 [9.6]
Education, No. [%]
Low 723 [17.9]
Mid-low 1,200 [29.7]
Mid-high 961 [23.8]
High 1,154 [28.6]
History of smoking, No. any time [%] 924 [22.9]
Prenatal psychopathology score, median f90% rangeg 0.16 f0.02–0.63g
Serum folate, nmol/l, median f90% rangeg 17.70 f8.08–31.20g
Serum C-reactive protein, median f90% rangeg 4.40 f1.20–13.30g
Thyroid parameters
Age of biological father at enrollment, yr, mean (SD) 33.5 (5.4)
Time of blood sampling, median weeks of gestation f90% rangeg 13.1 f11.4–16.1g
Thyrotropin, mU/l, median f90% rangeg 1.37 f0.45–2.95g
fT4, pmol/l, median f90% rangeg 14.88 f11.82–18.91g
Thyroid peroxidase antibodies, No. yes [%] 308 [7.6]
Hypothyroxinemia, No. yes [%]
Mild, fT4 < 11.82 pmol/l 295 [7.3]
Severe, fT4 < 10.99 pmol/l 136 [3.4]
Child
Age, yr, median f90% rangeg 5.9 f5.7–6.5g
Male sex, No. [%] 2,026 [50.2]
Ethnicity, No. Western [%] 2,965 [73.4]
Birth weight, g, mean (SD) 3,428 (566)
Gestational age at birth, wk, median f90% rangeg 39.9 f37.9–41.7g
Intelligence, score (SD) 102.4 (14.7)
Pervasive Developmental Problems score, median f90% rangeg 2.00 f0.00–5.00g
Social Responsiveness Scale score, median f90% rangeg 0.17 f0.00–0.45g
fT4 5 free thyroxine; No. 5 number of cases; SD 5 standard deviation.
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TABLE 3. Linear Regression Analyses of Early Gestation Maternal Thyroid Function and Autistic Symptoms in
the Offspring, n 5 4,039
Maternal Thyroid Parameters Autistic Symptoms at Age 6 Years, Scores
Pervasive Developmental
Problems Social Responsiveness Scale
B (95% CI) p B (95% CI) p
TSH per SD 0.01 (20.02 to 0.03) 0.68 0.01 (20.001 to 0.01) 0.12
fT4 per SD 20.03 (20.06 to 20.01) 0.04 20.002 (20.01 to 0.01) 0.67
Mild hypothyroxinemia 0.09 (20.02 to 0.19) 0.10 0.02 (20.01 to 0.04) 0.33
Only mild hypothyroxinemia 20.04 (20.17 to 0.004) 0.62 20.02 (20.06 to 0.02) 0.28
Severe hypothyroxinemia 0.23 (0.07 to 0.37) 0.04 0.05 (0.01,0.10) 0.01
TPO-Abs1 0.05 (20.08 to 0.18) 0.43 0.03 (20.01 to 0.06) 0.11
Mild hypothyroxinemia (n 5 136): 0.03 < TSH < 2.5mIU/l and fT4 < 11.82pmol/l (<10th percentile of the sample); only
mild hypothyroxinemia (n 5 295): 0.03 < TSH < 2.5mIU/l and 10.99 < fT4 < 11.82pmol/l; severe hypothyroxinemia (n 5
159): 0.03 < TSH < 2.5mIU/l and fT4 < 10.99pmol/l (<5th percentile); TPO-Abs
1 (n 5 308): 100IU/ml.
Models were adjusted for child’s sex, ethnicity, gestational age at birth, birth weight, maternal age, educational level, smoking his-
tory, prenatal psychopathology, thyroid medication during pregnancy, parity, marital status, maternal folate and C-reactive protein
levels in early pregnancy, time of thyroid sampling during pregnancy, and paternal age. For the results of the additional adjustment
for child’s intelligence, please see the text.
The B’s are not interpretable, as the mathematically transformed scores were used in the analyses.
CI 5 confidence interval; fT4 5 free thyroxine; SD 5 standard deviation; TPO-Abs 5 thyroid peroxidase antibodies; TSH 5
thyrotropin.
TABLE 2. Multivariate Logistic Regression Analyses of Early Gestation Maternal Thyroid Function and Autistic
Symptoms in the Offspring, n 5 4,039
Maternal Thyroid Parameters Pervasive Developmental Problems at Age 6 Years
Borderline Problems
n 5 263
Clinical Problems
n 5 123
OR (95% CI) p OR (95% CI) p
TSH per SD 0.91 (0.77–1.07) 0.27 0.92 (0.72–1.17) 0.49
fT4 per SD 0.93 (0.80–1.09) 0.37 0.95 (0.77–1.17) 0.62
Mild hypothyroxinemia 1.31 (0.84–2.04) 0.23 1.41 (0.78–2.57) 0.26
Only mild hypothyroxinemia 0.77 (0.38–1.55) 0.46 0.51 (0.16–1.64) 0.26
Severe hypothyroxinemia 2.02 (1.16–3.51) 0.01 2.60 (1.30–5.18) 0.01
TPO-Abs1 1.47 (0.85–2.55) 0.17 0.78 (0.28–2.16) 0.63
Mild hypothyroxinemia (n 5 136): 0.03 < TSH < 2.5mIU/l and fT4 < 11.82pmol/l (<10th percentile of the sample); only
mild hypothyroxinemia (n 5 295): 0.03 < TSH < 2.5mIU/l and 10.99 < fT4 < 11.82pmol/l; severe hypothyroxinemia (n 5
159): 0.03 < TSH < 2.5mIU/l and fT4 < 10.99pmol/l (<5th percentile); TPO-Abs
1 (n 5 308): 100IU/ml.
Models were adjusted for child’s sex, ethnicity, gestational age at birth, birth weight, maternal age, educational level, smoking his-
tory, prenatal psychopathology, thyroid medication during pregnancy, parity, marital status, maternal folate and C-reactive protein
levels in early pregnancy, time of thyroid sampling during pregnancy, and paternal age. For the results of the additional adjustment
for child’s intelligence, please see the text.
CI 5 confidence interval; fT4 5 free thyroxine; OR 5 odds ratio; SD 5 standard deviation; TPO-Abs 5 thyroid peroxidase anti-
bodies; TSH 5 thyrotropin.
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symptoms in the child, perhaps as a result of alterations
of neuronal migration in the developing brain.
Our study has several strengths, such as the large
population-based sample and a unique prospective
design, but we were faced with some limitations. First,
we measured maternal thyroid parameters once during
pregnancy. However, the measurements were performed
during early gestation, as recommended.4 Second, we
used parental reports of autistic-like behaviors. Clinical
diagnosis based on interviews and direct observations is
unfeasible in large samples; instead, parental reports of
children’s behavior have been used widely in epidemio-
logical studies.20,21,23–25 There are limitations to parental
reports of children’s social deficits, including parental
inability to detect impaired dyadic interactions.33 How-
ever, parents are ideal observers of certain aspects of
social behavior, such as smiles, and are often familiar
with their child’s functioning in different settings across
time.34 In a sample of 2,719 children from the Interac-
tive Autism Networks,35 the parent-reported SRS scores
were considerably higher in ASD children than in their
siblings (see Supplementary Table 1). Additionally, Mura-
tori et al24 reported a sensitivity of 0.85 and specificity
of 0.90 for the CBCL11=2-5 PDP subscale to differentiate
ASD children from children with typical development.
In our study, the number of children with clinical diag-
nosis of ASD was unavailable; however, by using strin-
gent criteria and combining 2 instruments, we defined
80 children at high risk of developing ASD. Third, as in
many epidemiological studies, in Generation R we
observed nonresponse (72% participation rate in early
pregnancy) and loss to follow-up (21% loss to follow-up
at 6 years). The nonresponse may affect the generalizabil-
ity of the findings and could introduce a selection bias in
the study.36,37 However, we showed that the participation
rate at age 6 years was unrelated to maternal fT4. This
finding, together with the relatively low loss to follow-
up, makes it less likely that our results were affected by
selection bias.
Thyroid hormones are critical during pregnancy.
Maternal hypothyroidism causes pregnancy complica-
tions, including postpartum hemorrhage, placental
abruption, and preterm labor; some of these are risk fac-
tors for autism.38 Thyroid deficiency in utero during
critical periods of brain development causes mental retar-
dation, psychomotor delay, and deafness.5,6,39 It is also
associated with other neurodevelopmental outcomes such
as cerebral palsy.40 In the fetal brain, the prohormone T4
is converted into the active thyroid hormone 3,5,30-triio-
dothyronine (T3) via 5
0 deiodination of maternal thyro-
xine by local brain type 2 iodothyronine deiodinase
(D2).
39 T3 binds to nuclear thyroid hormone receptors
that regulate gene expression in the brain.39 These recep-
tors appear in the cerebral cortex of the human fetus by
the 8th to 9th weeks of gestation and increase about 10-
fold between the 10th and 18th weeks of gestation,39
concurrently with increased D2 activity to augment T3
cortical levels. Therefore, moderately low T4 maternal
levels may be damaging to the cortical formation of the
fetus.
Children with autism have increased head circum-
ference, excessive brain growth, cortical and white matter
abnormalities dated to early pregnancy in brain imag-
ing,41 and significantly more neurons in the prefrontal
cortex, particularly in the dorsolateral region (79% more
neurons than control cases, ie, 1.57 vs 0.88 billion; 95%
CI 5 0.66–1.10).42 Neuropathologically, autism is a
defect of neurogenesis and neuronal migration, causing
abnormal cortical laminar patterns, focal cortical dyspla-
sia, excessive neuronal counts, and cell immaturity with
densely packed neurons in hippocampus, subiculum,
mammillary body, septal nuclei, and amygdala.11,43
In humans, neocortical neurons derived from the
neuroepithelium migrate from periventricular regions
between weeks 12 and 24 of gestation.44 Migration
occurs along radial glia scaffolds, with late born neurons
migrating past early born neurons.44 Cajal-Retzius neu-
rons secrete reelin,45 an extracellular glycoprotein that
binds to membrane receptors on migrating neurons
phosphorylating the disabled homolog-1 (Dab1) to stop
neuronal migration.
The reelin–dab signaling system is dependent on
thyroid hormones.46 Hypothyroidism reduces reelin
expression and enhances Dab1 expression during brain
development.47 Fatemi and her group45,47,48
FIGURE 2: Maternal hypothyroxinemia in early pregnancy
and autistic symptoms in the children at age 6 years.
Roman et al: Maternal Thyroxine and Autism
November 2013 739
demonstrated reelin signaling abnormalities in autism.
Alterations included significant reductions in reelin pro-
tein, reelin mRNA, and Dab1 mRNA along with eleva-
tions in Reln receptor, and VLDL-R mRNA in frontal
and cerebellar cortex.47,48 Recently, liver X receptor beta
(LXRb) interactions with thyroid hormone receptor
alpha (THRa) in brain cortical layering were described.49
Some studies have found genetic susceptibility poly-
morphisms of the reelin gene (RELN) in autism; however,
other comprehensive studies have been negative, suggest-
ing that environmental factors probably play an important
role in the disruption of this signaling system.1
The neuropathological abnormalities of autism
could be explained by disruption of the reelin–dab sig-
naling system resulting from early maternal hypothyroxi-
nemia. Maternal T4 and T3 are transported to the fetal
brain across the blood–brain barrier, but prior to the for-
mation of the fetal thyroid around midgestation the fetus
is unable to produce thyroxine and is, therefore, com-
pletely dependent on maternal thyroxine.5,39 Maternal
serum levels of thyrotropin increase progressively during
normal pregnancy, causing a corresponding rise of serum
thyroglobulin.5 Transfer of maternal T4 to the fetus
occurs up to birth; therefore, the availability of fT4 to
embryonic and fetal tissues is dependent on circulating
maternal T4. Decreases in fT4 occur in hypothyroxinemic
women even if they are clinically euthyroid.5,6
In conclusion, the association of severe maternal
hypothyroxinemia early in pregnancy with significant
increase in risk of parent-reported autistic symptoms is
concordant with epidemiological, clinical, neuropatholog-
ical, molecular biological, genetic, and experimental data
on autism. Currently, it is recommended to treat overt
maternal thyroid dysfunction in pregnancy because of
potentially serious consequences for the child.50 However,
the evidence is inconclusive as to whether children of
hypothyroxinemic mothers would benefit from treat-
ment. Although our findings cannot establish causality,
they provide further support for the possible role of low
maternal thyroid function in children’s brain develop-
ment. Future studies are recommended to apply long-
term follow-up of children to obtain more meaningful
performance estimates.51 If confirmed by future research,
this study provides arguments in favor of universal
thyroid-function screening in the first trimester of preg-
nancy52 and may open the possibility of preventive inter-
vention in autism.
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